Germ Cell Tumor Global Market Report 2024

The germ cell tumor market size has grown rapidly in recent years. It will grow from $8.81 billion in 2023 to $10.17 billion in 2024 at a compound annual growth rate (CAGR) of 15.5%. The growth observed during the historical period can be ascribed to heightened awareness, collaborative endeavors, government initiatives, and enhanced patient access to healthcare.

The germ cell tumor market size is expected to see rapid growth in the next few years. It will grow to $17.3 billion in 2028 at a compound annual growth rate (CAGR) of 14.2%. The anticipated growth in the forecast period can be credited to the emergence of therapies, personalized medicine, genomic research, the global healthcare infrastructure, and patient-centric approaches. Significant trends expected during the forecast period comprise the integration of digital health, increased focus on research and development, advancements in diagnostic technologies, global shifts in epidemiology, and technological progress in diagnosis.

The anticipated surge in the number of clinical trials is expected to drive the expansion of the germ cell tumor market in the future. Clinical trials, meticulously crafted research studies involving human participants, serve to evaluate the safety, effectiveness, and potential benefits of new medical interventions, treatments, therapies, or procedures. They hold significant importance in the exploration of germ-cell cancers, aiding in the assessment of novel medicines' efficacy and safety while providing valuable data on the current course of treatment. A report by Xtalks, a Canada-based digital health company, reveals that as of May 2023, there are 452,604 registered clinical trials globally on ClinicalTrials.gov. Among these, 64,838 trials are actively recruiting participants, marking a substantial increase from the reported over 365,000 trials in early 2021. Consequently, the growing number of clinical trials is a key driver behind the expansion of the germ cell tumor market.

The rising prevalence of cancer is poised to fuel the growth of the germ cell tumor market in the coming years. Cancer, characterized by the uncontrolled growth and spread of abnormal cells leading to tumor formation, remains a significant health concern. The primary treatment for germ cell tumors involves surgical removal of the tumor followed by chemotherapy to target any remaining cancer cells. In 2023, the American Cancer Society Inc. projects that 1,958,310 new cancer cases will be diagnosed in the US, compared to 1,918,030 in 2022. This increase underscores the escalating prevalence of cancer and, consequently, propels the growth of the germ cell tumor market.

The potential for side effects associated with the use of anti-tumor drugs is expected to hinder the growth of the germ cell tumor market. Survivors treated with anti-tumor medications face the risk of long-term side effects, including hearing loss and kidney damage, which may impede market growth. Notably, the National Library of Medicine in the US highlights a significant and severe side effect linked to the use of cyclophosphamide, which is the potential induction of hemorrhagic cystitis. Hence, the germ cell tumor market faces constraints due to the substantial risk of side effects associated with anti-tumor drugs.

Leading companies in the germ cell tumor market are actively forming partnerships to enhance their profitability. For example, in August 2022, Merck & Co. Inc., a US-based pharmaceutical company focusing on germ cell tumor medicine, entered into a collaboration with Orna Therapeutics, a US-based biotechnology company. This collaboration aims to accelerate the development of RNA therapies for patients requiring new treatment options by leveraging the combined expertise of both organizations. Additionally, in June 2022, Truveta Inc., a US-based healthcare company, partnered with Pfizer Inc., a US-based pharmaceutical company engaged in clinical trials and research on germ cell malignancies. This collaboration aims to utilize Truveta's health data platform to provide Pfizer with an advanced data platform for research, bringing together life science and health systems to expedite real-time safety insights.

In September 2022, CytoReason Ltd., an Israel-based biotechnology company, collaborated with Pfizer Inc. to provide AI for drug discovery and development. Through this agreement, Pfizer's drug research activities will incorporate the company's AI technologies. The arrangement, valued at up to $110 million over the next five years, involves Pfizer contributing $20 million in stock, offering options to license CytoReason's platform and disease models, and providing additional project support. Pfizer Inc., recognized as one of the market participants actively involved in clinical trials and research on germ cell malignancies, solidifies its position through strategic collaborations such as these.

Major companies operating in the germ cell tumor market report are Johnson & Johnson, Pfizer Inc., F. Hoffmann-La Roche AG, Abbvie Inc., Bayer AG, Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Fresenius Kabi Oncology Limited, Sanofi S.A., AstraZeneca plc, Ipsen Pharma, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Regeneron Pharmaceuticals Inc., Sandoz International GmbH, Daiichi Sankyo Co. Ltd., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ono Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, Taiho Pharmaceutical Co. Ltd., Accord Healthcare Limited, Spectrum Pharmaceuticals Inc., Ziopharm Oncology Inc.

North America was the largest region in the germ cell tumors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the germ cell tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the germ cell tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The germ cell tumors market includes revenues earned by entities by providing services such as surgical services, imaging, psychosocial support, genetic counseling, and pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The germ cell tumors market also includes sales of etoposide, ifosfamide, dactinomycin, bleomycin, and cisplatin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary germ cell tumor diseases encompass those affecting the testicles, ovaries, and other areas. 'Testicular' pertains to any medical condition impacting the testicles, the male reproductive organs responsible for sperm and hormone production, such as testosterone. Treatment modalities involve chemotherapy and immunotherapy, with drug administration occurring through oral, intravenous, or intraperitoneal routes. Diverse end users, including hospitals, clinics, and research institutes, play roles in the management of these conditions.

The germ cell tumor market research report is one of a series of new reports that provides germ cell tumor market statistics, including germ cell tumor industry global market size, regional shares, competitors with a germ cell tumor market share, detailed germ cell tumor market segments, market trends and opportunities, and any further data you may need to thrive in the germ cell tumor industry. This germ cell tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.